{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:36:06Z","timestamp":1790087766872,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07820-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:01:38Z","timestamp":1751382098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China"],"prefix":"10.1038","volume":"15","author":[{"given":"Shuzhen","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"2","key":"7820_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3947\/ic.2015.47.2.81","volume":"47","author":"DJ Hong","year":"2015","unstructured":"Hong, D. J. et al. Epidemiology and characteristics of metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa. Infect. Chemotherapy 47(2), 81\u201397 (2015).","journal-title":"Infect. Chemotherapy"},{"issue":"1","key":"7820_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12941-016-0148-y","volume":"15","author":"J Li","year":"2016","unstructured":"Li, J. et al. Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China. Ann. Clin. Microbiol. Antimicrob. 15(1), 35 (2016).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"1","key":"7820_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12866-024-03321-5","volume":"24","author":"MA Abdelaziz","year":"2024","unstructured":"Abdelaziz, M. A., El-Aziz, A. M. A., El-Sokkary, M. M. A. & Barwa, R. Characterization and genetic analysis of extensively drug-resistant hospital acquired Pseudomonas aeruginosa isolates. BMC Microbiol. 24(1), 225 (2024).","journal-title":"BMC Microbiol."},{"issue":"7","key":"7820_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00355-19","volume":"63","author":"DJ Diekema","year":"2019","unstructured":"Diekema, D. J. et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemotherapy 63(7), 10\u20131128 (2019).","journal-title":"Antimicrob. Agents Chemotherapy"},{"issue":"3","key":"7820_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10096-024-04750-w","volume":"43","author":"G Peirano","year":"2024","unstructured":"Peirano, G., Matsumara, Y., Nobrega, D., Church, D. & Pitout, J. D. D. Population-based genomic surveillance of Pseudomonas aeruginosa causing bloodstream infections in a large Canadian health region. Eur. J. Clin. Microbiol. Infect. Dis. 43(3), 501\u2013510 (2024).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"3","key":"7820_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2017.08.015","volume":"51","author":"LH Tsao","year":"2018","unstructured":"Tsao, L. H. et al. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa. J. Microbiol. Immunol. Infect. 51(3), 359\u2013366 (2018).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"7820_CR7","doi-asserted-by":"publisher","first-page":"1294141","DOI":"10.3389\/fpubh.2023.1294141","volume":"11","author":"S Xiao","year":"2024","unstructured":"Xiao, S., Liang, X., Han, L. & Zhao, S. Incidence, antimicrobial resistance and mortality of Pseudomonas aeruginosa bloodstream infections among hospitalized patients in China: A retrospective observational multicenter cohort study from 2017 to 2021. Front. Public Health 11, 1294141 (2024).","journal-title":"Front. Public Health"},{"key":"7820_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/IDR.S238811","volume":"13","author":"RM Abd El-Baky","year":"2020","unstructured":"Abd El-Baky, R. M. et al. Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Infect. Drug Res. 13, 323\u2013332 (2020).","journal-title":"Infect. Drug Res."},{"issue":"9","key":"7820_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.07.003","volume":"5","author":"T Jesudason","year":"2024","unstructured":"Jesudason, T. WHO publishes updated list of bacterial priority pathogens. Lancet Microbe. 5(9), 100940 (2024).","journal-title":"Lancet Microbe."},{"key":"7820_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jgar.2021.03.032","volume":"26","author":"K Yang","year":"2021","unstructured":"Yang, K. et al. Socio-economic burden of bloodstream infections caused by carbapenem-resistant and carbapenem-susceptible Pseudomonas aeruginosa in China. J. Global Antimicrob. Res. 26, 101\u2013107 (2021).","journal-title":"J. Global Antimicrob. Res."},{"issue":"6","key":"7820_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/QCO.0000000000000768","volume":"34","author":"S Herrera","year":"2021","unstructured":"Herrera, S., Bodro, M. & Soriano, A. Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections. Curr. Opin. Infect. Dis. 34(6), 686\u2013692 (2021).","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"3","key":"7820_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cmi.2019.07.002","volume":"26","author":"D Viasus","year":"2020","unstructured":"Viasus, D. et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin. Microbiol. Infect. 26(3), 345\u2013350 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"7820_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhin.2004.03.022","volume":"57","author":"C Defez","year":"2004","unstructured":"Defez, C. et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57, 209\u2013216 (2004).","journal-title":"J. Hosp. Infect."},{"issue":"1","key":"7820_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3324\/haematol.2010.036640","volume":"96","author":"EM Trecarichi","year":"2011","unstructured":"Trecarichi, E. M. et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 96(1), e1\u2013e3 (2011).","journal-title":"Haematologica"},{"key":"7820_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jgar.2024.03.018","volume":"37","author":"F Yuan","year":"2024","unstructured":"Yuan, F., Li, M., Wang, X. & Fu, Y. Risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: A 10-year retrospective study. J. Global Antimicrob. Res. 37, 150\u2013156 (2024).","journal-title":"J. Global Antimicrob. Res."},{"issue":"8","key":"7820_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/INF.0000000000003563","volume":"41","author":"L Li","year":"2022","unstructured":"Li, L., Huang, Y., Tang, Q. & Zheng, Y. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in children. Pediatric Infect. Dis. J. 41(8), 642\u2013647 (2022).","journal-title":"Pediatric Infect. Dis. J."},{"issue":"3","key":"7820_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","volume":"16","author":"JS Garner","year":"1988","unstructured":"Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C. & Hughes, J. M. CDC definitions for nosocomial infections 1988. Am. J. Infect. Control. 16(3), 128\u2013140 (1988).","journal-title":"Am. J. Infect. Control."},{"issue":"3","key":"7820_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"7820_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","volume":"10","author":"R Han","year":"2020","unstructured":"Han, R. et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China. Front. Cell. Infect. Microbiol. 10, 314 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"7820_CR20","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1093\/cid\/cit278","volume":"57","author":"EJ Baron","year":"2013","unstructured":"Baron, E. J. et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin. Infect. Dis. 57(4), e22\u2013e121 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"7820_CR21","doi-asserted-by":"publisher","first-page":"1168096","DOI":"10.3389\/fcimb.2023.1168096","volume":"13","author":"S Patil","year":"2023","unstructured":"Patil, S. et al. Resistance genomics and molecular epidemiology of high-risk clones of ESBL-producing Pseudomonas aeruginosa in young children. Front. Cell. Infect. Microbiol. 13, 1168096 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"7820_CR22","unstructured":"Pa, W. Clinical and laboratory standards institute (CLSI): Performance standards for antimicrobial susceptibility testing. 31st ed. Wayne PA. 2021;CLSI supplement M100 (2021)."},{"issue":"8","key":"7820_CR23","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1017\/ice.2020.1351","volume":"42","author":"S Zhao","year":"2021","unstructured":"Zhao, S. et al. Risk factors for carbapenemase-producing organisms among inpatients in Scotland: A national matched case-control study. Infect. Control Hosp. Epidemiol. 42(8), 968\u2013977 (2021).","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"Suppl 4","key":"7820_CR24","doi-asserted-by":"publisher","first-page":"s386","DOI":"10.1093\/cid\/ciaa1522","volume":"71","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa bloodstream infection in adult patients with acute Leukemia. Clin. Infect. Dis. 71(Suppl 4), s386\u2013s393 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"7820_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.diagmicrobio.2017.06.017","volume":"89","author":"T Khadem","year":"2017","unstructured":"Khadem, T. et al. Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study. Diagn. Microbiol. Infect. Dis. 89, 146\u2013150 (2017).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"7820_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jhin.2024.03.022","volume":"149","author":"NEG Rodr\u00edguez","year":"2024","unstructured":"Rodr\u00edguez, N. E. G. et al. Pseudomonas aeruginosa bloodstream infections in children and adolescents: Risk factors associated with carbapenem resistance and mortality. J. Hosp. Infect. 149, 56\u201364 (2024).","journal-title":"J. Hosp. Infect."},{"issue":"5","key":"7820_CR27","first-page":"1624","volume":"160","author":"J Zupetic","year":"2021","unstructured":"Zupetic, J. et al. Elastase activity from Pseudomonas aeruginosa respiratory isolates and ICU mortality. Chest Infect. Original Res. 160(5), 1624\u20131633 (2021).","journal-title":"Chest Infect. Original Res."},{"issue":"10","key":"7820_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0954411914556137","volume":"228","author":"S Veerachamy","year":"2014","unstructured":"Veerachamy, S., Yarlagadda, T., Manivasagam, G. & Yarlagadda, P. K. Bacterial adherence and biofilm formation on medical implants: a review. Proc. Inst. Mech. Eng. [H] 228(10), 1083\u20131099 (2014).","journal-title":"Proc. Inst. Mech. Eng. [H]"},{"issue":"1","key":"7820_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1473-3099(24)00456-0","volume":"25","author":"SME Kuijpers","year":"2025","unstructured":"Kuijpers, S. M. E. et al. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: An umbrella review. Lancet Infect Dis. 25(1), 94\u2013113 (2025).","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"7820_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","volume":"49","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches, I. et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 49(6), 615\u2013632 (2023).","journal-title":"Intensive Care Med."},{"key":"7820_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.micpath.2014.07.008","volume":"74","author":"SA El-Mowafy","year":"2014","unstructured":"El-Mowafy, S. A., Abd El Galil, K. H., El-Messery, S. M. & Shaaban, M. I. Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa. Microb. Pathog. 74, 25\u201332 (2014).","journal-title":"Microb. Pathog."},{"key":"7820_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114415","volume":"247","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. From quorum sensing inhibition to antimicrobial defense: The dual role of eugenol-gold nanoparticles against carbapenem-resistant Pseudomonas aeruginosa. Colloids Surf B Biointerfaces 247, 114415 (2025).","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"08","key":"7820_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3855\/jidc.10150","volume":"12","author":"D Zhang","year":"2018","unstructured":"Zhang, D. et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection or colonization in a Chinese teaching hospital. J. Infection Dev. Countries 12(08), 642\u2013648 (2018).","journal-title":"J. Infection Dev. Countries"},{"key":"7820_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/IDR.S396428","volume":"16","author":"X Wei","year":"2023","unstructured":"Wei, X. et al. Risk factors and outcomes of patients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infection. Infect. Drug Res. 16, 337\u2013345 (2023).","journal-title":"Infect. Drug Res."},{"issue":"Supplement_4","key":"7820_CR35","doi-asserted-by":"publisher","first-page":"S386","DOI":"10.1093\/cid\/ciaa1522","volume":"71","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa bloodstream infection in adult patients with acute Leukemia. Clin. Infect. Dis. 71(Supplement_4), S386\u2013S393 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"7820_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13756-020-00728-3","volume":"9","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob. Res. Infect. Control 9(1), 79 (2020).","journal-title":"Antimicrob. Res. Infect. Control"},{"issue":"10","key":"7820_CR37","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.ajic.2011.12.014","volume":"40","author":"K Ku","year":"2012","unstructured":"Ku, K. et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and\/or carbapenem-resistant enterobacteriaceae infections. Am. J. Infect. Control 40(10), 983\u2013987 (2012).","journal-title":"Am. J. Infect. Control"},{"issue":"10474","key":"7820_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic, N., Uhlemann, A. C. & Peleg, A. Y. Multidrug-resistant Gram-negative bacterial infections. Lancet 405(10474), 257\u2013272 (2025).","journal-title":"Lancet"},{"issue":"5","key":"7820_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jiph.2024.03.010","volume":"17","author":"W Katip","year":"2024","unstructured":"Katip, W. et al. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis. J. Infect. Public Health 17(5), 727\u2013734 (2024).","journal-title":"J. Infect. Public Health"},{"issue":"8","key":"7820_CR40","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiph.2023.05.024","volume":"16","author":"W Katip","year":"2023","unstructured":"Katip, W., Rayanakorn, A., Oberdorfer, P., Taruangsri, P. & Nampuan, T. Short versus long course of colistin treatment for carbapenem-resistant Acinetobacter baumannii in critically ill patients: A propensity score matching study. J. Infect. Public Health 16(8), 1249\u20131255 (2023).","journal-title":"J. Infect. Public Health"},{"issue":"3","key":"7820_CR41","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/jac\/dkae466","volume":"80","author":"SH Kim","year":"2025","unstructured":"Kim, S. H. et al. Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: A time-kill assay. J. Antimicrob. Chemother. 80(3), 738\u2013745 (2025).","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"7820_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","volume":"44","author":"TP Lodise Jr","year":"2007","unstructured":"Lodise, T. P. Jr., Lomaestro, B. & Drusano, G. L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44(3), 357\u2013363 (2007).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"7820_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1590\/1806-9282.20220493","volume":"69","author":"U Co\u015fkun","year":"2023","unstructured":"Co\u015fkun, U. & Dagcioglu, Y. Evaluation of toxin-antitoxin genes, antibiotic resistance, and virulence genes in Pseudomonas aeruginosa isolates. Rev. Assoc. Med. Bras. 69(1), 51\u201355 (2023).","journal-title":"Rev. Assoc. Med. Bras."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07820-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:21:41Z","timestamp":1751383301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7820"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07820-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The research protocol was reviewed and approved by Ruijin Hospital Ethics Committee and Xiangya hospital Ethics Committee (reference number: KY2023-083, 202212318). The need for informed consent was waived by the Review Boards of Ruijin Hospital and Xiangya Hospital due to the observational retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"20719"}}